Your browser doesn't support javascript.
loading
PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.
Alhesa, Ahmad; Awad, Heyam; Bloukh, Sarah; Al-Balas, Mahmoud; El-Sadoni, Mohammed; Qattan, Duaa; Azab, Bilal; Saleh, Tareq.
Afiliação
  • Alhesa A; Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 54658The University of Jordan, Amman, Jordan.
  • Awad H; Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 54658The University of Jordan, Amman, Jordan.
  • Bloukh S; Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 54658The University of Jordan, Amman, Jordan.
  • Al-Balas M; Department of General and Specialized Surgery, Faculty of Medicine, 34419The Hashemite University, Zarqa, Jordan.
  • El-Sadoni M; Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 54658The University of Jordan, Amman, Jordan.
  • Qattan D; Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 54658The University of Jordan, Amman, Jordan.
  • Azab B; Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 54658The University of Jordan, Amman, Jordan.
  • Saleh T; Department of Pathology and Cell Biology, 21611Columbia University Irving Medical Center, New York, NY, USA.
Int J Immunopathol Pharmacol ; 36: 3946320221078433, 2022.
Article em En | MEDLINE | ID: mdl-35225058
ABSTRACT

OBJECTIVES:

To investigate the expression of programmed death-ligand 1 (PD-L1) in breast cancer in association with incomplete pathological response (PR) to neoadjuvant chemotherapy (NAC).

METHODS:

PD-L1 expression was evaluated using immunohistochemistry in post-operative, post-NAC samples of 60 patients (n = 60) diagnosed with breast invasive ductal carcinoma with incomplete PR to NAC, including 31 matched pre-NAC and post-NAC samples (n = 31). PD-L1 protein expression was assessed using three scoring approaches, including the tumor proportion score (TPS), the immune cell score (ICS), and the combined tumor and immune cell score (combined positive score, CPS) with a 1% cut-off.

RESULTS:

In the post-operative, post-NAC samples (n = 60), positive expression rate of PD-L1 was observed in 18.3% (11/60) of cases by TPS, 31.7% (19/60) by ICS, and 25% (15/60) by CPS. In matched samples, positive expression rate of PD-L1 was observed in 19.3% (6/31) of patients by TPS, 51.6% (16/31) by ICS, and 19.3% (6/31) by CPS in pre-NAC specimens, while it was observed in 22.6% (7/31) of matched post-NAC samples by TPS, 22.6% (7/31) by ICS, and 19.3% (6/31) by CPS. In the matched samples, there was a significant decrease in PD-L1 immunoexpression using ICS in post-NAC specimens (McNemar's, p = 0.020), while no significant differences were found using TPS and CPS between pre- and post-NAC samples (p = 1.000, p = 0.617; respectively). PD-L1 immunoexpression determined by TPS or CPS was only significantly associated with ER status (p = 0.022, p = 0.021; respectively), but not with other clinicopathological variables. We could not establish a correlation between PD-L1 expression and the overall survival rate (p > 0.05). There were no significant differences in the tumor infiltrating lymphocytes count between the paired pre- and post-NAC samples (t = 0.581, p = 0.563 or Wilcoxon's Signed Rank test; z = -0.625, p = 0.529).

CONCLUSION:

Our findings indicate that PD-L1 protein expression in infiltrating immune cells was significantly reduced in breast tumors that developed incomplete PR following the exposure to NAC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Ductal / Antígeno B7-H1 Limite: Humans Idioma: En Revista: Int J Immunopathol Pharmacol Assunto da revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA / PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Jordânia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Ductal / Antígeno B7-H1 Limite: Humans Idioma: En Revista: Int J Immunopathol Pharmacol Assunto da revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA / PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Jordânia